Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Sees Significant Growth in Short Interest

Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) was the recipient of a significant growth in short interest in the month of September. As of September 15th, there was short interest totaling 13,500 shares, a growth of 214.0% from the August 31st total of 4,300 shares. Based on an average daily trading volume, of 69,700 shares, the days-to-cover ratio is presently 0.2 days. Based on an average daily trading volume, of 69,700 shares, the days-to-cover ratio is presently 0.2 days.

Analyst Ratings Changes

BDRX has been the subject of several analyst reports. Weiss Ratings reissued a “sell (e)” rating on shares of Biodexa Pharmaceuticals in a report on Saturday, September 27th. Wall Street Zen cut shares of Biodexa Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Saturday, August 2nd. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

Biodexa Pharmaceuticals Stock Performance

BDRX stock opened at $6.70 on Friday. Biodexa Pharmaceuticals has a 1-year low of $5.00 and a 1-year high of $108.90. The business has a 50 day simple moving average of $6.54 and a two-hundred day simple moving average of $10.23.

About Biodexa Pharmaceuticals

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.